Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,624 across all filing types
Latest filing 2023-08-21 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2023-08-21 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023
Interim / Quarterly Report Classification · 95% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2023' and contains detailed financial data such as revenue, gross profit, expenses, and loss figures for the six-month period ending June 30, 2023. It also includes a Management Discussion and Analysis section, business highlights, product pipeline updates, and clinical trial progress. The document length is about 15,000 characters, indicating it is a substantive report rather than a brief announcement. The content and structure align with a comprehensive interim or quarterly financial report rather than a simple earnings release or announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR), which includes actual financial statements and substantive financial data and analysis for a period shorter than a full fiscal year. H1 2023
2023-08-21 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from Overseas Chinese Town (Asia) Holdings Limited regarding the date of a Board meeting to consider and approve the interim results for the six months ended 30 June 2023 and the declaration of an interim dividend. The document does not contain the actual interim financial results or detailed financial data but merely announces the upcoming meeting where such results will be considered. The document length is short (1525 characters) and it is clearly an announcement of a future event related to financial reporting, not the report itself. Therefore, it fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement rather than an Interim Report (IR) or Earnings Release (ER).
2023-08-21 English
PROFIT WARNING
Capital/Financing Update Classification · 95% confidence The document is titled 'PROFIT WARNING' and is an announcement made pursuant to the Listing Rules of the Hong Kong Stock Exchange. It provides a preliminary assessment of the company's expected loss for the six months ended 30 June 2023, based on unaudited consolidated management accounts. It explicitly states that the final financial results are still being finalized and will be disclosed in a forthcoming interim results announcement. The document is relatively short (3852 characters) and serves as an early alert to shareholders and investors about expected financial performance, not a full financial report. This fits the profile of a Capital/Financing Update or Earnings Release. However, since it is a profit warning about expected results for an interim period and not the actual earnings release, it is best classified as a Capital/Financing Update (CAP) because it updates on financial expectations and potential impact on capital markets rather than reporting finalized earnings. The document is not a full Interim Report (IR) as it lacks actual financial statements or substantive financial data, nor is it an Earnings Release (ER) which typically announces finalized quarterly or periodical results. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-08-21 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of RemeGen Co., Ltd. stating the date of a board meeting to consider and approve the interim results for the six months ended June 30, 2023. The document does not contain the actual interim financial results or substantive financial data but merely announces the upcoming meeting and the intention to publish the interim results. The document length is short (1496 characters) and fits the pattern of a report publication announcement or a meeting notice rather than the report itself. Therefore, according to the MENU VS MEAL RULE, this is not the interim report but an announcement related to it. The best fitting category is Regulatory Filings (RNS) as it is a general regulatory announcement about the board meeting and upcoming interim results publication, not the report itself.
2023-08-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return on movements in securities, specifically focusing on authorized and issued share capital, share options, and confirmations related to securities issued by the company. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with listing rules under the Stock Exchange of Hong Kong. The content is regulatory in nature, reporting share capital and share issuance movements, but it does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report but a regulatory filing of share capital movements and confirmations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-02 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.